Human erythrocytes interact with particles or soluble immune complexes bearing C3b, the major fragment of the third component of complement. This phenomenon is known as immune adherence (1). B lymphocytes (2), neutrophils, macrophages, monocytes (3-5), and epithelial cells of the kidney glomerulus (6) also have membrane receptors for C3b. The C3b receptors function in phagocytosis, facilitating the attachment of the particle to the phagocytes, and, in synergy with the Fc receptors for IgG, promote ingestion of sensitized particles (7, 8). Recently, a glycoprotein of 205,000 mol wt has been isolated from the membrane of human erythrocytes and identified as the C3b receptor (CR1) (9, 10). This protein was characterized as an inhibitor of the alternative pathway C3 convertase (C3b,Bb) and as a cofactor for the cleavage of the a' chain of C3b in the fluid phase by a serum enzyme, C3b/C4b inactivator.
Cellular Intermediates. EAC1, EAC14, EAC14°xY2, and EAC14°xY23 were prepared from antibody (IgG)-sensitized sheep erythrocytes (EA) by reacting sequentially with 300 site-forming units (SFU) of Clgp, C4hu, ~YC2hu, and C3hu until the corresponding stage of each of the intermediate cells was reached. EAC14 cells bearing 1.0-1.5 C4 sites/cell were prepared by incubating EA with excess C1 (300 SFU) and limiting amounts of C4hu. The cells were referred to as EAC 14~, EAC 142~, EAC 14°~2~, EAC 14°~23t~, and EAC°~235~,., and were prepared in the same manner, except that the limiting components were the final ones in each intermediate.
Complement
Receptor. CR 1 was purified by sequential column chromatography on Biorex-70 (Bio-Rad Laboratories, Richmond, Calif.), Sepharose-lentil lectin, and Sepharose-C3 affinity chromatography, according to the method of Fearon (9) . During purification, CR 1 was assayed by its inhibitory activity for C3 convertase either of the classical (C4b,2a) or the alternative (C3b,Bb,P) pathway. Inhibition of the alternative pathway C3 convertase was assayed as previously described (9) . Inhibition of the classical pathway C3 convertase was assayed as follows: 100 #1 of EAC142r~, 1 × 10S/ml, was incubated with 100 #1 of samples from fractions diluted in DGVB for 15 min at 30°C. Residual C4b,2a activity was developed by adding 1.3 ml of guinea pig serum diluted 1:50 with EDTA-GVB, followed by incubation at 37°C for 60 min. The protein concentration of CR1 was estimated by a modified Folin method (25) using bovine serum albumin (BSA) as a standard.
Radiolabeling. C4 was labeled with x26I by means of Enzymobeads (Bio-Rad Laboratories).
25 #g of C4 in 25 #1 was incubated with 50 #1 of Enzymobeads, 1 mCi ofl~I (Amersham Corp., Arlington Heights, Ill.), and 25 /xl of 2% glucose. After incubation for 20 min at 0°C, the reaction was stopped by addition of 50 #1 of 0.05% sodium azide. Free iodine was removed by dialysis. The specific activity was 4 X 10 e cpm/1 #g protein, a~I-C4b was prepared by incubation of 25 #g 1~I-C4 with 1 #g of Cls at 37°C for 2 h.
CR1 was labeled by the same method used for C4, and separated from the free iodine as follows: the labeled mixture was diluted with 0.1% Nonidet P-40 (NP-40; Particle Data, Inc., Elmhurst, Ill.) and applied to a 0.3-ml Biorex-70 column equilibrated with 0.05 M phosphate buffer, pH 7.2, containing 0.02 M NaCI and 0.1% NP-40. The column was washed extensively 125 in the starting buffer and I-CR1 was eluted with 0.5 M NaC1. The specific activity was 7 × 104 cpm/1 #g protein.
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE). This was performed
according to the method of Laemmli (26) . 10% running and 5% stacking gels were used. For labeled samples, radioautography was carried out by exposing the dried gel to an X-Omat R film (XR-5; Eastman Kodak Company, Rochester, N. Y.) at -70°C overnight. For estimation of the molecular weight of the bands, the following standards were used: 200,000 myosin (H chain); 92,500 phosphorylase B; 68,000 BSA; 43,000 ovalhumin; 25,700 a-chymotrypsinogen; and 18,400 ~-lactoglobulin.
Results
Purification of an Inhibitor of C4b,2a from Human E~ythrocyte Membranes. The inhibitory factor was isolated from human erythrocytes as described by Fearon (9) , except that the membranes originating from 2 X 10 is erythrocytes were washed extensively in a Pellicon Cassette System (Millipore Corp., Bedford, Mass.), and concentrated to a volume of 300 ml before solubilization in detergent and loading in a Biorex-70 column. The activity of the inhibitor was followed by two assays; that is, the decaydissociation of C4b,2a and C3b,Bb,P formed on sheep erythrocytes. During all steps of purification, the two activities coincided as illustrated in Fig. 1 .30/~1 of the purified inhibitor at a concentration of 200 #g/ml gave a single stained band in SDS-PAGE under reducing or nonreducing conditions, with a molecular weight close to 200,000. Therefore, a single glycoprotein from human erythrocyte membranes, identified as the complement receptor (CR1) of cells (10) , inhibits the activity of the C3 convertase of both the classical and alternative pathways. (33 Convertase . The inhibitory activity of CR1 on C3 consumption by C4b,2a was directly shown as follows: EAC 14°xY2 cells were prepared with 300 SFU of Clgp, C4hu, and °xYC2hu. Samples (0.2 ml, 2 × l0 T cells) were incubated with equal volumes of various dilutions of CR 1 in DGVB for 30 min at 30°C. The cells were washed twice by centrifugation, the pellets were incubated with 0.2 ml of purified human C3 (36 SFU) for 30 rain at 30°C, and the residual C3 hemolytic activity was determined. The results showed a dose-dependent inhibition of C3 consumption by CR1 (Fig. 2) . The effects could be observed at concentrations of the receptor <50 ng/ml.
Mechanism of Inhibition of the Classical Pathway
The experiments illustrated in Fig. 3 A demonstrate that this inhibitory activity is associated with the decay of C4b,2a sites from the EAC142 cells. Erythrocyte intermediates were prepared with 300 SFU of C 1 and C4, but with limiting amounts of C2. The EAC 142~m cells were incubated with equal volumes of various dilutions of CR 1 at 30°C and the time course of the C4b,2a decay was studied. The half-life of the enzyme was considerably shortened in the presence of the receptors in a doserelated manner. For example, at a concentration of CR1 of 95 ng/ml, the half-life of the C4b,2a sites was 4.5 rain, whereas in controls incubated with buffer, the half-life was 8 min. Stabilized enzyme C4b°~Y2a was also inhibited (Fig. 3 B) . 
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Fro. 2. Inactivation of C3-convertase activity by CRI. 0.2 ml of EAC14°~2 cells (1 X 10S/ml) was incubated with an equal volume of CR1 for 30 min at 30°C and washed twice with DGVB. 0.2 ml of purified human C3 was added to each pellet. After 30 min of incubation at 30°C, supernatant fluids were separated and the residual C3 hemolytic activities were determined. The amount of C3 initially available (36 SFU) was calculated from the samples incubated with EAC14. (1), 95 (A) and 190 (I--I) ng/ml, and incubated at 30°C. At timed intervals, 200#1 samples were withdrawn, and 1.3 ml of guinea pig serum diluted 1:50 with EDTA-GVB was added. The mixtures were incubated for 60 min at 37°C to develop lysis. In the experiment using °~C2, samples were washed twice after incubation with
CRi+
Because C4-bp and CR 1 have similar effects on the classical pathway C3 convertase (27), we compared their activities and found that CR1 was the superior inhibitor (Fig. 4) . On a weight basis, -5-10 times less CR1 than C4-bp was necessary to inactivate the same number of C4b,2a sites. Due to nonspecific aggregation, micelle formation, or assembly of polymers, the apparent molecular weight of either protein by gel filtration under nondenaturing conditions is -1 X 10 e.
Because the immune adherence receptor hinds C4b (11, 12) , the most likely explanation for the inhibitory activity of CR1 on C4h,2a is that CR1 competes with C2 for a binding site on C4b. This was investigated by radiolabeling CR1 and studying its incorporation onto EAC14 in the presence or absence of C2. In preliminary experiments, in which various erythrocyte intermediates were incubated with 12sI-radiolabeled CR1, we found that a maximum of 20% of the counts could be incorporated on EAC14, whereas only 3% bound EAC 1 (data not shown). 2 Next, we studied the inhibitory effects of C2. Samples of EACI4°XY2 cells were prepared with serially diluted °xYC2 and incubated with 100 #1 of a~I-CR1 (0.14 #g protein) at 30°C for 30 min. After washing, the binding of CR1 to cells was determined. Fig. 5 shows that °~YC2 prevented the binding of I~I-CR1 to cells in a dose-dependent fashion. As a control, we found that purified factor B had no effect on the incorporation of lzsI-CR1 on EAC14 cells. In all experiments so far described, the activity of CR1 on C4b,2a was studied on erythrocyte intermediates prepared with excess C4 (300 SFU). Under these conditions, it might be difficult to detect any direct and irreversible effects of CR1 on C4b. To investigate this possibility, we incubated samples of EAC14tim (0.83 sites/cell) with CRI alone, or with CR1 plus C3b/C4b inactivator, or with buffer alone for 30 min at 30°C and measured the remaining hemolytic activity. As positive controls, other samples of EAC14u~ were incubated with C3b/C4b inactivator, C4-bp, or mixtures of these two proteins. As shown in Fig. 6, CR1 and C4-bp alone did not influence the hemolytic activity of EAC14um even at concentrations of 1.5 and 15 #g/ml, respectively. Furthermore, neither protein enhanced the enzymatic activity of C3b/C4b inactivator on the EAC14 cells, s This is in sharp contrast to the results of previous experiments showing that at concentrations 10 times smaller, CR1 inactivated 0.8 C4b,2a sites per EACi42~ cell (Fig. 4) . About 43% of the counts bound to EA1423, probably reflecting a higher affinity of CR1 for C3b than for C4b. a A previous report from our laboratory indicated that C4-bp enhances the cleavage of C4b by C3b/ C4b inactivator (27). This conclusion was based mainly on the observation that C4-bp and C3b/C4b inactivator had synergistic inhibitory effects on the hemolytic activity of EAC142~ (rather than on EAC14~., which was used in the present experiments). In light of the results shown in Fig. 4 , the pronounced diminution of C4b,2a sites on EAC142~ treated with C4-bp plus C3b/C4b inactivator, which we previously observed, could reflect an increased displacement of C2 by the combined activities of C4-bp and enzyme. This would not be without precedent, because C3b/C4b inactivator binds stoichiometrically to C3b in the presence of~lH (28). Taken together, these observations support the idea that CR 1 and C2a compete for the same or similar sites on C4b, and that this may be the only basis for the inhibitory effects of CR 1 on the classical pathway C3 convertase.
Inhibition of Classical Pathway (35 Convertase.
The effect of CR 1 on the classical pathway C5 convertase was investigated by measuring the hemolytic activity of EAC14°xY231a~ (100 #1, 107 cells) after incubation with serially diluted CR1 for 30 min at 30°C. The results are shown in Fig. 7 . In the presence of 10 ng/ml of CR1, 50% of the available sites of C5 convertase were inhibited; that is, about 0.6 sites/cell. This After reduction with 2-mercaptoethanol, samples were analyzed by 10% SDS-PAGE, followed by radioautography. CR1 functioned as an essential cofactor for the proteolysis of C4b by C3b/C4b inactivator. The a' chain of C4b is cleaved into fragments a2, a3, and a4, in mixtures containing both CRI and C3b/C4b inactivator, but it is not affected in the presence of either protein alone.
c o n c e n t r a t i o n o f C R 1 is three times smaller t h a n t h a t necessary to i n a c t i v a t e the s a m e n u m b e r o f C 4 b , 2 a sites (Fig. 4) . A similar e x p e r i m e n t was p e r f o r m e d to e x a m i n e the effects o f C R l o n EAC14°~Y235Um (0.7 sites/cell). In contrast to its i n h i b i t o r y activities on EAC142tim a n d EACI423nm, C R 1 was totally inactive on EAC142351im even at c o n c e n t r a t i o n s o f 800 n g / m l ( d a t a not shown).
Activity of CRI on C4b in the Fluid Phase. T h e previous e x p e r i m e n t s d e m o n s t r a t e d
that, like C4-bp, C R 1 p r o m o t e s the decay-dissociation o f the classical p a t h w a y C3 convertase. three fragments, a2, a3, and a4, with apparent molecular weights of 44,000, 27,000, and 17,000, respectively. By SDS-PAGE, the fragments originating from the cofactor activities of CR1 and C4-bp are indistinguishable. From the results of several experiments, the cofactor activity of C4-bp is between two and four times higher than that of CR1 on a weight basis. Discussion It has been shown previously that CR1 inhibits the alternative pathway C3 convertase (C3b,Bb,P) by enhancing the decay of Bb (9) . The main finding of this paper is that CR1 also inhibits the C3 and C5 convertases of the classical pathway (C4b,2a and C4b,2a,3b) .
In purifying functional CR1 to homogeneity, we monitored activity with two assays, i.e., the inhibition of hemolytic function of C4b,2a and C3b,Bb,P assembled on the erythrocyte surface. We found throughout the isolation procedure that both activities were similarly distributed. The final preparations showed a single polypeptide chain in either the reduced or unreduced form, with a molecular weight of ~200,000 (Fig. 1) . At low concentrations, the purified protein inhibited the consumption of C3 by C4b,2a (Fig. 2) . On the basis of these findings, we conclude that CR1 inhibits the classical pathway C3 convertase, an enzyme whose active site is in C2a, but whose function is C4b dependent.
Other cell-associated decay-accelerating factors of the classical pathway C3 convertase have previously been described. Several years ago, Hoffman found such an activity in crude butanol extracts ofstroma from human red cells (29) . More recently, Burge et al (30) isolated an inhibitor of C4b,2a from guinea pig erythrocytes. Its properties are similar to those of CR1, which suggests that they may be homologous proteins.
The mechanism of inhibition of C4b,2a by CR1 probably consists of competitive displacement of C2a from C4b. This is indicated by observations that the purified receptor enhances the decay of the hemolytic activity of EAC142 (Fig. 3) and that °xYC2 inhibits the binding of 12SI-CR 1 to EAC 14 cells (Fig. 5) . The possibility of direct effects of CR 1 on C4b was excluded in experiments showing that CR 1 alone did not inhibit the hemolytic activity of EAC 14~, nor did it enhance the inactivation of the cell-bound C4b by C3b/C4b inactivator (Fig. 6) .
It is of interest that the overall effects of CR1 and the serum protein C4-bp on EAC14, EAC142, and fluid phase C4b are similar, although quantitative differences were noticed. Neither protein irreversibly influences the hemolytic function of EAC 14am; both promote decay of EA142, and both serve as cofactors for the cleavage of fluid phase C4b. However, on a weight basis, CR I is a much better inhibitor of EAC142 than C4-bp (Fig. 4) , although as a cofactor, C4-bp is apparently more efficient (Fig. 8) .
CR1 is also a powerful inhibitor of the classical pathway C5 convertase EAC 14°xY23Um. In this complex enzyme, the proteolytic site resides on the C2a subunit and C3b provides an essential anchorage site for the substrate C5 (31-34). Although we have not further investigated the mechanisms whereby CR 1 inhibits C5 convertase, it is likely that CR1 competes with the substrate C5 for a binding site on the C3b subunit of the enzyme. Under the experimental conditions used, an effect of CR1 on the other subunits, C4b°XY2a, seems less likely, because these components were present in great excess on the erythrocytes. Moreover, the inhibitory effects on EAC 14°'Y23tt~ were detected at concentrations of CR1 below those necessary to inactivate EAC14°xY2nm.
In short, CR1 controls the activity of all amplifying enzymes of the complement cascade that are C3b or C4b dependent, presumably by decay-dissociation of C2 (or factor B), by inhibiting the C3b-C5b interaction, or by serving as a cofactor for the cleavage of the a' chain of C4b (and C3b) by C3b/C4b inactivator. Therefore, CR 1 is a powerful membrane-associated inhibitor of the complement system whose functional properties encompass those of the plasma proteins C4-bp and fllH (Table I) .
Because CR 1 inhibits C3b,Bb,P, Fearon (9) proposed that the presence of CR 1 on cell membranes may prevent inappropriate self recognition by complement. This hypothesis was put forward in the context of recent insights into the mechanisms of activation of the alternative pathway (43) (44) (45) . According to these ideas, low level deposition of C3b, through its metastable binding site, occurs continuously in vivo, both on autologous cells and on foreign particles. Whether the cascade will proceed or not depends on the interaction between C3b and certain cell surface structures not yet well characterized. One of these structures, according to Fearon, might be CR1, which would bind to C3b already deposited on another site of the membrane and prevent the formation of an intrinsic C3 convertase, C3b,Bb. This hypothesis necessitates both fruitful and rapid collisions between the two membrane-associated moieties.
On the basis of the present findings, it is our view that CR1 can function as an inhibitor of enzymes extrinsic to the cells bearing the receptor. A well-known function of CR 1 is to promote adherence of C3b-and C4b-bearing substrates to phagocytes. This interaction, however, could result in a microenvironment potentially damaging to the plasma membrane of the responding cell. Thus, complement-bearing immune complexes or bacteria, in close proximity to the host cell, might promote local activation and deposition of complement components, with attendant lethal consequences for the host cell. Seen in this context, the ability of some phagocytic cells to synthesize and secrete several complement components, including C3 and C4, might aggravate these effects.
We therefore wish to propose that CR1 on the surface of cells supplies an increased local concentration of a strong inhibitor of complement activation, and, therefore, provides cells with a mechanism for circumventing damage, while at the same time interacting with complement-bearing substrates. The view that complement receptors are also complement inhibitors suggests new ideas about their role on the membrane of nonphagocytic cells. For example, it raises the possibility that CR1 protects B lymphocytes from the damaging effects of the complement activation that might occur in their vicinity, after the specific binding of antigen or of antigen-antibody complexes to Fc receptors. In summary, the present observations show that complement receptors of cell membranes are functionally homologous to the plasma proteins fllH and C4-bp, and suggest that these receptors or similar structures may provide a selective advantage to cells or organisms that, at some time during their life history, may come in close contact with antigen-antibody complexes and complement. Of course, further experiments are necessary to test this hypothesis directly.
While this paper was being prepared for submission, findings similar to ours were brought to our attention (46) . Summary A glycoprotein from the membrane of human erythrocytes has been identified as a receptor for C3b (CR1). It promotes the dissociation of the alternative pathway C3 convertase C3b,Bb and the cleavage of C3b by C3b/C4b inactivator. We find that CR1 also inactivates the C3 and C5 convertases of the classical pathway.
CRI inhibits the consumption of C3 by C3 convertase EAC142 and enhances the decay of C4b,2a sites. On a weight basis, CR1 is ~5-10 times more active than C4 binding protein, a serum inhibitor of C4b,2a. The binding of 12nI-CR1 to EAC14 cells is inhibited by C2. Therefore, it is likely that CR 1 and C2 compete for a site on C4b. CR 1 inhibited C5 convertase even more effectively, but had no effect on the assembly of the late complement components.
At high concentrations, CR 1 alone has no irreversible effects on cell-bound C4b. In the fluid phase, CR 1 can function as a cofactor for the cleavage of the a' chain of C4b by C3b/C4b inactivator.
A well-known function of CR1 is to promote adherence of microbes or immune complexes bearing C3b and C4b to cells. This interaction could result in a microenvironment damaging to the plasma membrane of the responding cell because the extrinsic C3b and C4b fragments can serve as additional sites of assembly of enzymes of the cascade. We therefore wish to propose that CR 1 on the surface of cells supplies an increased local concentration of a strong inhibitor of the amplifying enzymes of the complement system and provides cells with a mechanism for circumventing damage when they bind C3b-and C4b-bearing substrates.
